Rapid Micro Biosystems, Inc. announced that it is reaffirming its prior full year 2022 outlook for revenue of between $27 million and $32 million, representing growth of approximately 25% to 50% as compared to the full year 2021. The Company's full year 2022 revenue outlook assumes that roughly 30% of the revenue will be delivered in the first half of the year, with the remaining 70% in the second half.